FDA Grants CIMZIA Breakthrough Designation in High-Risk Obstetric APS

Evidence Company disclosure · Discovery September 9, 2026 · Importance 4/5 · Direction Positive Summary UCB disclosed that FDA granted Breakthrough Therapy Designation to certolizumab pegol for preventing placenta-mediated adverse pregnancy outcomes in pregnant patients with antiphospholipid syndrome who are persistently lupus-anticoagulant positive and have…